HOME >> BIOLOGY >> NEWS
Mayo Clinic researchers enhance safety and effectiveness of therapeutic virus that fights cancer

Rochester, Minn. -- Mayo Clinic researchers working with colleagues in Germany have devised a much-needed multilevel safety feature for viruses used to treat cancer. In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a modified measles virus that turns on only in the presence of secretions specific to malignant cancer cells.

In effect, the Mayo Clinic virus makeover uses proteins secreted by cancer cells as the unique key to the virus' ignition. Their report on the topic appears in the Aug. 1 edition of Cancer Research (http://cancerres.aacrjournals.org).

The investigation was performed in laboratory mice that were transplanted with a human cancer. The process is still experimental -- and thus, years away from clinical use in humans. However, the Mayo results may be immediately useful in designing improved cancer treatments for humans. "Our work shows that oncolytic measles virus particle activation can be made dependent on substances secreted by cancer cells, and this enhances safety," explains Roberto Cattaneo, Ph.D., lead researcher on the Mayo team. "By doing this, our study broadens the safeguarding strategies possible to tightly restrict the targeted virus to cancer cells."

Significance of the Mayo Clinic Research
The Mayo researchers say their contribution is a key advance because it provides a method of designing a therapeutic virus that is safe, stable and that reliably targets and kills cancer cells. Importantly, it appears to greatly reduce the possibility that the virus would erroneously turn on and harm the patient by causing unintended infection.

As such, the Mayo innovation of the cancer-activated virus is a helpful safety advance for the promising experimental field of "oncolytic virotherapy." The phrase refers to t
'"/>

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
1-Aug-2006


Page: 1 2

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
4. NIH awards VBI, Mayo Clinic $2.4M to study chronic rhinosinusitis
5. Clinical trial for diabetic macular edema
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
8. Arizona State University and Mayo Clinic join forces to develop cancer vaccine
9. Marshfield Clinics electronic health record first to receive CCHIT certification
10. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
11. October MCP: A special issue on Clinical Proteomics

Post Your Comments:
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
(Date:8/27/2015)... Aug. 27, 2015  Neogen Corporation (NASDAQ: NEOG ... of United Kingdom -based Lab M ... media and diagnostic systems. Lab M ... leading provider of microbial testing and diagnostic products for ... The company currently sells into more than 70 countries ...
(Date:8/27/2015)... 2015 HUYA Bioscience International (HUYA) today announced the ... Society of HTLV-1, held this week at the University ... the Society is to promote research on HTLV-1 and ... technology and research related to these fields to advance ... is proud to support this prestigious conference," said ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a commercial ... relationship of genetics and hypertension at the International Academy of Cardiology ... Columbia, Canada. The event, which boasts an extensive overview of the latest research ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
Cached News: